The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Barriers to CAR-T driving non-receipt after referral at a large academic center
Jae Park, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the barriers to immune effector cell therapy, specifically CAR T-cell therapy, in patients with hematologic malignancies. Dr Park highlights that despite the high effectiveness of CAR T-cell therapy, approximately 40% of patients with lymphoma or myeloma referred to his institution for consideration did not receive the treatment, with the primary reasons being the patient’s disease status or disease burden at the time of referral and logistical barriers. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
